Answers by TheMediTary.Com - Last updated: 23-Jul-2023
Aimovig (erenumab-aooe) works by blocking the receptor of calcitonin gene-related peptide (CGRP) which is thought to contribute to the vasodilation and inflammation associated with migraine.
Aimovig is a fully human monoclonal antibody and is the first in the class of calcitonin gene-related peptide (CGRP) receptor antagonists for migraine prevention.
Aimovig is given once-a-month by subcutaneous (under the skin) self-injections with an auto-injector pen or a single-dose prefilled syringe.